The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare ...
The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...
Sri Lanka is experiencing a rise in Chikungunya cases, with the highest number of infections being reported across the ...
The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...
At least five suspected cases of chikungunya were recorded in Davao City in January 2025. The residents who were suspected of ...
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results